CTIS2024-512506-25-00进行中（未招募）1 期
Rituximab-induced remission in CIDP (ReCIX study)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Inclusion criteria Group 1 (new patients): - CIDP according to the EAN/PNS criteria - Untreated - Men and women aged between 18 and 80 years - Sufficient CIDP-related disability, as judged by treating physician to warrant IVIg and RTX treatment - Capable of giving signed informed consent, Inclusion criteria Group 2 (patients on maintenance treatment IVIg or SCIg): - CIDP according to the EAN/PNS criteria on maintenance treatment (stable dose/interval of at least 4 infusions or 3 months), including one of the following categories: a) patients with wear-off symptoms before next IVIg infusion captured by at least the minimal clinical important difference (MCID) on at least one outcome measure b) patients with a failed withdrawal attempt in the last 12 months captured by at least an MCID on at least one outcome measure c) patients with an increase of IVIg/SCIg dose/interval in the last 12 months leading to improvement by at least the MCID on at least one outcome measure, see below. We will use the most commonly used MCID criteria, namely: 1) one point on the INCAT disability score (1-10); 2) 4 points on a centile score on I-RODS (disability, 1-100); 3) 2 points on the MRC sum score (muscle strength, 0-60) and 4) 8 kPa on Vigorimeter (grip strength, single or both arms, variable range). - Men and women aged between 18 and 80 years - Capable of giving signed informed consent.
排除标准
- •Use of drugs associated with a demyelinating neuropathy in the last six months, IVIg interval of once every 6 weeks or more than 6 weeks (applies to Group 2 only), Obesity (BMI > 35), Known active malignancy, (not in remission), currently treated with chemotherapy or immunomodulatory drugs, or with a life expectancy of less than 1 year., History of recurrent/chronic infections, Active, severe infections (such as tuberculosis, sepsis and opportunistic infections), Patients in a severely immunocompromised state, Severe heart failure (New York Heart Association Class IV) or severe, uncontrolled cardiac disease., Serious co-morbidity as judged by treating physician., Pregnancy or nursing mother; intention to become pregnant during the course of the study; female patients of childbearing potential either not using or not willing to use a medically reliable method of contraception for the entire duration of the study., No written informed consent, Known serious adverse events with previous IVIg or RTX treatment. Hypersensitivity to RTX or any component of the formulation. Hypersensitivity to the human immunoglobulins or to any of the excipients. Known selective IgA deficiency patients who developed antibodies to IgA., Paranodopathy with demonstrated (paranodal) antibodies, previously considered part of CIDP spectrum (in these cases rituximab is preferred treatment), Positive hepatitis B and C serology suggesting active/untreated infection (HBsAg, anti-HB core en anti-HBs and HCV antistof (IgG)), Ongoing immunosuppressive treatment for other indications., Immunosuppressive treatment other than (already discontinued) corticosteroids in last 6 months.
研究者
相似试验
尚未招募
2 期
Rituximab maintenance therapy in nephrotic syndromeCTRI/2022/02/040186Dr Arpita Raychaudhury
已完成
不适用
ncontrolled trial of Rituximab treatment on refractory or steroid dependent nephrotic syndrome in adult.refractory or steroid dependent nephrotic syndromeJPRN-UMIN000014355Saitama Medical University Department of Nephrology5
进行中（未招募）
不适用
First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study.Asociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea del linfoma folicular - R-CVP-IFEUCTR2005-004761-42-ESFundacion Leucemia y Linfoma
已完成
2 期
Rituximab in treatment of Rheumatoid arthritis in Indian patientsCTRI/2017/08/009321CENTER FOR RHEUMATIC DISEASES60
尚未招募
不适用
The Effect of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) on Overall Survival of Patients with Relapsed Diffuse Large B-Cell Lymphoma Post-Autologous Stem Cell Transplantdiffuse large B-cell lymphomaACTRN12610000803099Haematology and Oncology Clinics (HOCA) Research Centre150